Kidney Cancer

Share this journal
Kidney Cancer - journal
ISSN print
2468-4562
ISSN online
2468-4570
Volume
4; 4 issues
Status
Last issue (4:1) published on 31 March 2020
Next issue
4:2 scheduled for June 2020
Back volumes
1-3
Website
journalkidneycancer.com
Subject
Cancer Research, Medicine & Health, Urology

APCs Waived Article processing charges (APCs) are currently waived for Kidney Cancer, and content is currently published as Open Access.

Sign Ups & Social Media –
Be sure to sign up to the KCA journal newsletter to receive alerts of new issues and other journal news. Sign up via this link tiny.cc/KCAsignup & you can read the latest newsletter here. To follow us on social media, find our Twitter account at @KCA_Journal and keep updated as we share our journal content and news of interest to the kidney cancer research community. And, importantly, you can join in the discussion with our research community!

Kid .Can. Assoc. Partnership –
As of Nov 2017, a new partnership was announced between the Kidney Cancer Association (kidneycancer.org) and our journal Kidney Cancer, which is a forum for important scientific advancements and the advocacy community.

Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the kidney. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the kidney.

Editors-in-Chief

Primo N. Lara, Jr., MD
University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA
Email: kca@iospress.com

Peter Mulders, MD, PhD
Radboud UMC
Nijmegen, The Netherlands
Email: kca@iospress.com

Associate Editors

Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA

Axel Bex, MD, PhD
Netherlands Cancer Institute, Amsterdam, The Netherlands

Toni K. Choueiri, MD
Dana-Farber Cancer Institute, Boston, USA

Viktor Grünwald, MD
University Hospital Essen, Essen, Germany

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center, Houston, USA

Bradley C. Leibovich, MD
Mayo Clinic, Rochester, USA

Egbert Oosterwijk, PhD
Radboud UMC, Nijmegen, The Netherlands

Javier Puente, MD, PhD
Hospital Clinico Universitario San Carlos, Madrid, Spain

Sandy Srinivas, MD
Stanford University, Stanford, USA

Yoshihiko Tomita, MD, PhD
Niigata University, Niigata, Japan

Hirotsugu Uemura, MD, PhD
Kindai University Faculty of Medicine, Osaka, Japan

Christopher G. Wood, MD
The University of Texas MD Anderson Cancer Center, Houston, USA

Social Media Editor

Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA

Associate Editor for Reviews

Enrique Grande, MD
Anderson Cancer Center Madrid, Madrid, Spain

Sumanta Pal, MD
City of Hope, Duarte, USA

Editor of Clinical Trials Corner

Mamta Parikh, MD
UC Davis Comprehensive Cancer Center, Sacramento, USA

Editorial Board

Hideyuki Akaza, MD
University of Tokyo, Tokyo, Japan

Georg A. Bjarnason, MD, FRCP(C)
Sunnybrook Odette Cancer Center, Toronto, Canada

William P. Bro
Kidney Cancer Association, Chicago, USA

James Brugarolas, MD, PhD
University of Texas Southwestern Medical Center, Dallas, USA

Ronald M. Bukowski, MD
Cleveland Clinic Foundation, Cleveland, USA

Steven C. Campbell, MD, PhD
Cleveland Clinic, Cleveland, USA

Marc Dall’era, MD
UC Davis Comprehensive Cancer Center, Sacramento, USA

Tanya B. Dorff, MD
City of Hope, Duarte, USA

Janice P. Dutcher, MD
Cancer Research Foundation, Chappaqua, USA

Tim Eisen, PhD
University of Cambridge, Cambridge, United Kingdom

Bernard Escudier, MD
Institut Gustave Roussy, Villejuif, France

Robert A. Figlin, MD
Cedars-Sinai Medical Center, Los Angeles, USA

Thomas (Tom) Flaig, MD
University of Colorado School of Medicine, Aurora, USA

Jorge Garcia, MD
Cleveland Clinic, Cleveland, USA

Dan George, MD
Duke University School of Medicine, Durham, USA

Ugo De Giorgi, MD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

Martin Gore, PhD
The Royal Marsden Hospital and Instuitute of Cancer Research, London, United Kingdom

Rudolfo De Guzman, MD
National Kidney and Transplant Institute, Metro Manila, Philippines

John Haanen, MD, PhD
Netherlands Cancer Institute, Amsterdam, The Netherlands

Naomi Haas, MD
University of Pennsylvania, Philadelphia, USA

Hans Hammers, MD, PhD
University of Texas Southwestern, Dallas, USA

Michael R. Harrison, MD
Duke Cancer Institute, Durham, USA

Daniel Heng, MD, MPH
Tom Baker Cancer Center, Calgary, Canada

Michelle S. Hirsch, MD, PhD
Brigham and Women's Hospital, Harvard Medical School, Boston, USA

James J. Hsieh, MD, PhD
Washington University School of Medicine, St. Louis, USA

Thomas Hutson, DO, PharmD
US Oncology/Baylor, Houston, USA

Choung Soo Kim, MD, PhD
Asan Medical Center, Seoul, South Korea

Won Kim, MD
University of California San Francisco, San Francisco, USA

Christian Kollmannsberger, MD
BC Cancer Agency, Vancouver, Canada

James Larkin, MD, PhD
The Institute of Cancer Research, London, United Kingdom

Marston Linehan, MD
National Cancer Institute, Bethesda, USA

Borje Ljungberg, MD, PhD
Umeå University, Umeå, Sweden

Axel S. Merseburger, MD, PhD
University Hospital Schleswig-Holstein, Lübeck, Germany

Moshe C. Ornstein, MD
Cleveland Clinic, Cleveland, OH, USA

Susanne Osanto, MD, PhD
Leiden University Medical Center, Leiden, The Netherlands

Stephane Oudard, MD, PhD
Hôpital Européen Georges Pompidou, Paris, France

Allan J. Pantuck, MD
UCLA Institute of Urologic Oncology, Los Angeles, USA

Mamta Parikh, MD
University of California Davis Comprehensive Cancer Center, Sacramento, USA

Elizabeth Plimack, MD
Fox Chase Cancer Center, Philadelphia, USA

Camillo Porta, MD
IRCCS San Matteo University Hospital Foundation, Pavia, Italy

Thomas Powles, MD
The Royal Free NHS Trust and Barts Cancer Institute, London, United Kingdom

David I. Quinn, MBBS, PhD
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA

W. Kimryn (Kim) Rathmell, MD, PhD
Vanderbilt-Ingram Cancer Center, Nashville, USA

Bruce G. Redman, MD
University of Michigan, Ann Arbor, USA

Brian Rini, MD
Cleveland Clinic, Cleveland, USA

Paul Russo, MD
Memorial Sloan Kettering Cancer Center, New York, USA

Christopher Ryan, MD
Oregon Health Science University, Portland, USA

Manuela Schmidinger, MD
University of Austria, Vienna, Austria

Brian Shuch, MD
Yale School of Medicine/Smilow Cancer Center, New Haven, USA

Ramaprasad Srinivasan, MD, PhD
National Cancer Institute, Bethesda, USA

Walter Stadler, MD
University of Chicago, Chicago, USA

Mark Stein, MD
Rutgers, The State University of New Jersey, New Brunswick, USA

Cora N. Sternberg, MD
San Camillo and Forlanini Hospitals, Rome, Italy

Cezary Szczylik, MD, PhD
Oncology Military Medical Institute, Warsaw, Poland

Nizar M. Tannir, MD
MD Anderson Cancer Center, Houston, USA

Ilya Tsimafeyeu, MD
Kidney Cancer Research Bureau, Russian Society of Clinical Oncology, Moscow, Russia

Robert G. Uzzo, MD
Fox Chase Cancer Center, Philadelphia, USA

Ulka Vaishampayan, MD
Wayne State University, Karmanos Cancer Institute, Detroit, USA

Gretchen Vaughan
Kidney Cancer Association, Chicago, IL, USA

Guillermo de Velasco, MD, PhD
Hospital Universitario 12 de Octubre, Madrid, Spain

Nicholas J. Vogelzang, MD
Comprehensive Cancer Centers of Nevada (CCCN), Las Vegas, USA

Martin H. Voss, MD
Memorial Sloan Kettering Cancer Center, New York, USA

Stenio Zequi, MD, PhD
AC Camargo Cancer Center, Sao Paulo, Brazil

By submitting my article to this journal, I agree to the IOS Press License to Publish: iospress.com/service/authors/author-copyright-agreement and the IOS Press Privacy Policy: iospress.com/privacy-policy.

See instructions to authors.

Embase
Google Scholar

Use of Ibuprofen and Similar NSAIDs May Shorten Life of Patients with Metastatic Renal Cell Carcinoma

01 May 2018 - Amsterdam, NL – Ibuprofen, aspirin, and other non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs’ promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study in the journal Kidney Cancer indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC)....